arginine hydrochloride Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1549 74-79-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • l-arginine
  • L-Arg
  • arginine
  • arginine hydrochloride
  • arginine HCl
An essential amino acid that is physiologically active in the L-form.
  • Molecular weight: 174.20
  • Formula: C6H14N4O2
  • CLOGP: -3.52
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 5
  • TPSA: 125.22
  • ALOGS: -1.88
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 68 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 28, 1973 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 54.76 26.48 7 1067 38 46684950
Foetal growth restriction 54.23 26.48 15 1059 6552 46678436
Infantile apnoea 40.89 26.48 8 1066 768 46684220
Hyperammonaemia 39.97 26.48 11 1063 4705 46680283
Selective eating disorder 34.43 26.48 8 1066 1737 46683251
Cerebral haemorrhage 29.66 26.48 14 1060 28357 46656631
Device related sepsis 29.40 26.48 8 1066 3279 46681709
Extravasation 27.85 26.48 7 1067 2108 46682880
Ammonia increased 27.13 26.48 8 1066 4369 46680619

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 82.13 23.62 11 1190 47 29951230
Haematuria 68.19 23.62 34 1167 44800 29906477
Blindness cortical 63.67 23.62 11 1190 300 29950977
Hyperammonaemia 28.37 23.62 10 1191 5510 29945767

Pharmacologic Action:

SourceCodeDescription
ATC B05XB01 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTION ADDITIVES
Amino acids
ATC V03AF11 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:50733 nutritional supplement
CHEBI has role CHEBI:59163 biological marker
CHEBI has role CHEBI:75771 mus musculus metabolite
CHEBI has role CHEBI:76971 e.coli metabolites
CHEBI has role CHEBI:78675 essential metabolite
CHEBI has role CHEBI:75772 baker's yeast metabolite
CHEBI has role CHEBI:77746 h. sapiens metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diagnostic Test for Growth Hormone Secretion indication
Renal tubular acidosis contraindication 1776003 DOID:14219
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Constipation contraindication 14760008 DOID:2089
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Metabolic acidosis contraindication 59455009
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hb SS disease contraindication 127040003 DOID:10923
Osteolysis contraindication 203522001
Myocardial infarction in recovery phase contraindication 418044006
Allergic Reactions contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.97 acidic
pKa2 11.72 Basic
pKa3 8.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Nitric oxide synthase, inducible Enzyme Kd 5.15 CHEMBL

External reference:

IDSource
94ZLA3W45F UNII
4018668 VUID
N0000146979 NUI
D02982 KEGG_DRUG
1119-34-2 SECONDARY_CAS_RN
4018668 VANDF
4019067 VANDF
C0003765 UMLSCUI
CHEBI:29016 CHEBI
ARG PDB_CHEM_ID
CHEMBL1485 ChEMBL_ID
CHEMBL1200381 ChEMBL_ID
DB00125 DRUGBANK_ID
D001120 MESH_DESCRIPTOR_UI
6322 PUBCHEM_CID
1711 INN_ID
721 IUPHAR_LIGAND_ID
1091 RXNORM
14778 MMSL
206 MMSL
4219 MMSL
7609 MMSL
7610 MMSL
d00578 MMSL
000926 NDDF
005095 NDDF
52625008 SNOMEDCT_US
63676001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
R-Gene HUMAN PRESCRIPTION DRUG LABEL 1 0009-0436 INJECTION, SOLUTION 10 g INTRAVENOUS NDA 17 sections
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.29 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 1.20 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 1.47 g INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 1.47 g INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 1.47 g INTRAVENOUS ANDA 20 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9010 INJECTION, SOLUTION 0.95 g INTRAVENOUS NDA 24 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9011 INJECTION, SOLUTION 0.95 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 1.20 g INTRAVENOUS NDA 23 sections
FreAmine HBC HUMAN PRESCRIPTION DRUG LABEL 15 0264-9350 INJECTION, SOLUTION 0.58 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.73 g INTRAVENOUS NDA 23 sections
HepatAmine HUMAN PRESCRIPTION DRUG LABEL 16 0264-9371 INJECTION, SOLUTION 0.60 g INTRAVENOUS NDA 23 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 920 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 690 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0210 INJECTION 920 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0214 INJECTION 920 mg INTRAVENOUS NDA 20 sections
ProSol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0499 INJECTION, SOLUTION 1.96 g INTRAVENOUS NDA 21 sections
Clinisol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0502 INJECTION, SOLUTION 1.47 g INTRAVENOUS ANDA 18 sections
Travasol HUMAN PRESCRIPTION DRUG LABEL 15 0338-0644 INJECTION 1.15 g INTRAVENOUS NDA 20 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1089 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1091 INJECTION 489 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1099 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-1101 INJECTION 575 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 489 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1115 INJECTION 489 mg INTRAVENOUS NDA 20 sections